Table 4.
Result data from first 12 months of Xpert MTB/RIF implementation in nine countries
|
Xpert site |
Tests |
MTB Positive |
Rifampicin |
Failed Tests |
Type of failed test |
MTB + w/o failed tests |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
|
N |
% |
Sensitive |
Indeterminate |
Resistant |
n |
% |
Error |
Invalid |
No result |
|||||||
| n | % | N | % | n | % | N | % | n | % | n | % | |||||||
| Bangladesh |
1428 |
286 |
20.0% |
249 |
87.1% |
11 |
3.8% |
26 |
9.1% |
99 |
6.9% |
85 |
85.9% |
10 |
10.1% |
4 |
4.0% |
21.5% |
| Cambodia |
3697 |
768 |
20.8% |
741 |
96.5% |
22 |
2.9% |
5 |
0.7% |
439 |
11.9% |
169 |
38.5% |
264 |
60.1% |
6 |
1.4% |
23.6% |
| DR Congo |
6348 |
567 |
8.9% |
498 |
87.8% |
17 |
3.0% |
30 |
5.3% |
1032 |
16.3% |
868 |
84.1% |
107 |
10.4% |
57 |
5.5% |
10.7% |
| Kenya |
2803 |
258 |
9.2% |
238 |
92.2% |
11 |
4.3% |
9 |
3.5% |
266 |
9.5% |
240 |
90.2% |
23 |
8.6% |
3 |
1.1% |
10.2% |
| Malawi |
6258 |
632 |
10.1% |
602 |
93.5% |
9 |
1.4% |
21 |
3.3% |
853 |
13.6% |
546 |
64.0% |
265 |
31.1% |
42 |
4.9% |
11.7% |
| Moldova |
11472 |
1965 |
17.1% |
1227 |
62.4% |
48 |
2.4% |
690 |
35.1% |
673 |
5.9% |
387 |
61.7% |
105 |
15.6% |
181 |
26.9% |
18.2% |
| Mozambique |
6823 |
910 |
13.3% |
826 |
90.8% |
18 |
2.0% |
66 |
7.3% |
871 |
12.8% |
521 |
59.8% |
216 |
24.8% |
134 |
15.4% |
15.3% |
| Nepal |
6943 |
1376 |
19.8% |
1257 |
91.4% |
14 |
1.0% |
105 |
7.6% |
744 |
10.7% |
409 |
55.0% |
148 |
19.9% |
187 |
25.1% |
22.2% |
| Pakistan |
2201 |
433 |
19.7% |
390 |
90.1% |
13 |
3.0% |
30 |
6.9% |
130 |
5.9% |
77 |
59.2% |
37 |
28.5% |
16 |
12.3% |
20.9% |
|
All Countries |
47973 |
7195 |
15.0% |
6028 |
83.8% |
163 |
2.3% |
982 |
13.6% |
5107 |
10.6% |
3302 |
64.7% |
1175 |
23.0% |
630 |
12.3% |
16.8% |
| South Africa a | 1180669 | 171792 | 14.6% | 155811 | 90.7% | 2443 | 1.4% | 12266 | 7.1% | 32561 | 2.8% | 15.0% | ||||||
aReference 26. Data for South Africa is presented as a comparison after 25 months of implementation.